Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Graph

EDIT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $11.89M; Revenue including tax (m); Research and development $20.18M; Operating expenses $30.44M.
  • 2026-03-31: Revenue $2.83M; Revenue including tax (m); Research and development $17.60M; Operating expenses $27.83M.
  • 2025-12-31: Revenue $24.74M*; Revenue including tax (m); Research and development $27.40M*; Operating expenses $32.50M*.
  • 2025-09-30: Revenue $7.54M; Revenue including tax (m); Research and development $19.77M; Operating expenses $32.09M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

EDIT revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$11.89MRevenue$11.89MOperating expenses$30.44MOperating income-$18.55MOther income, net$17.00KResearch & development$20.18MNet income-$18.23M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesNet income
2026-06-30$11.89M(m)$20.18M$30.44M-$18.23M
2026-03-31$2.83M(m)$17.60M$27.83M-$24.98M
2025-12-31$24.74M*(m)$27.40M*$32.50M*-$5.62M*
2025-09-30$7.54M(m)$19.77M$32.09M-$25.12M
2025-06-30$3.58M(m)$16.18M$55.12M-$53.23M
2025-03-31$4.66M(m)$26.59M$80.82M-$76.09M
2024-09-30$61.00K(m)$47.64M$65.73M-$62.14M
2024-06-30$513.00K(m)$54.21M$72.42M-$67.61M
2024-03-31$1.14M(m)$48.79M$68.13M-$61.95M
2023-09-30$5.34M(m)$40.51M$55.50M-$45.02M
2023-06-30$2.89M(m)$29.78M$46.98M-$40.29M
2023-03-31$9.85M(m)$37.80M$60.81M-$49.04M
2022-09-30$42.00K(m)$41.33M$57.56M-$55.73M
2022-06-30$6.36M(m)$43.66M$60.60M-$53.45M
2022-03-31$6.77M(m)$37.98M$57.52M-$50.52M
2021-09-30$6.20M(m)$29.27M$45.45M-$39.08M
2021-06-30$379.00K(m)$33.75M$55.78M-$55.26M
2021-03-31$6.50M(m)$41.94M$63.38M-$56.73M
2020-12-31$11.42M(m)(m)$77.29M-$62.50M
2020-09-30$62.84M(m)$33.92M$53.85M$7.82M
2020-06-30$10.75M(m)$28.01M$42.09M-$23.57M
2020-03-31$5.72M(m)$34.57M$52.34M-$37.72M
2019-12-31$12.28M(m)(m)$51.71M-$37.77M
2019-09-30$3.85M(m)$22.70M$38.44M-$32.94M
2019-06-30$2.33M(m)$23.57M$37.98M-$33.79M
2019-03-31$2.07M(m)$15.84M$33.33M-$29.25M
2018-12-31$6.12M$6.12M(m)$32.37M-$25.05M
2018-09-30$14.52M$14.52M$17.44M$30.78M-$15.24M
2018-06-30$7.37M$7.37M$32.72M$47.03M-$38.72M
2018-03-31$3.93M$3.93M$21.30M$35.49M-$30.94M
2017-12-31(m)$3.67M(m)$40.11M-$36.19M
2017-09-30$6.28M$6.28M$20.40M$33.03M-$26.60M
2017-06-30$3.10M$3.10M$17.32M$29.21M-$26.44M
2017-03-31$682.00K$682.00K$19.02M$31.31M-$31.10M
2016-12-31(m)(m)(m)$39.88M-$39.38M
2016-09-30(m)(m)$10.83M$22.13M-$21.02M
2016-06-30(m)(m)$10.43M$22.59M-$19.04M
2016-03-31(m)(m)$8.88M$18.64M-$17.75M
2015-12-31(m)(m)(m)$13.16M-$12.63M
2015-09-30(m)(m)$3.85M$8.05M-$7.41M
2015-06-30(m)(m)$7.28M$10.56M-$47.57M
2015-03-31(m)(m)$1.89M$5.16M-$5.29M

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesNet income
2026-06-30$14.72M(m)$37.78M$58.28M-$43.21M
2025-06-30$8.24M(m)$42.77M$135.94M-$129.32M
2024-06-30$1.65M(m)$103.00M$140.54M-$129.56M
2023-06-30$12.74M(m)$67.58M$107.79M-$89.33M
2022-06-30$13.13M(m)$81.64M$118.12M-$103.97M
2021-06-30$6.88M(m)$75.69M$119.16M-$111.98M
2020-06-30$16.47M(m)$62.58M$94.43M-$61.30M
2019-06-30$4.40M(m)$39.41M$71.31M-$63.03M
2018-06-30$11.30M$11.30M$54.02M$82.52M-$69.66M
2017-06-30$3.78M(m)$36.34M$60.52M-$57.54M
2016-06-30(m)(m)$19.31M$41.23M-$36.79M
2015-06-30(m)(m)$9.17M$15.72M-$52.86M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesNet income
2025-09-30$15.78M(m)$62.55M$168.03M-$154.44M
2024-09-30$1.71M(m)$150.64M$206.27M-$191.70M
2023-09-30$18.07M(m)$108.09M$163.29M-$134.34M
2022-09-30$13.18M(m)$122.96M$175.68M-$159.69M
2021-09-30$13.07M(m)$104.95M$164.61M-$151.07M
2020-09-30$79.31M(m)$96.49M$148.28M-$53.48M
2019-09-30$8.25M(m)$62.11M$109.75M-$95.98M
2018-09-30$25.82M$25.82M$71.46M$113.29M-$84.90M
2017-09-30$10.06M(m)$56.73M$93.55M-$84.14M
2016-09-30(m)(m)$30.14M$63.36M-$57.81M
2015-09-30(m)(m)$13.02M$23.78M-$60.27M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$40.52M(m)$89.95M$200.53M$0.00-$160.06M
2024-12-31$32.31M(m)$199.25M$283.47M$0.00-$237.09M
2023-12-31$78.12M(m)$177.65M$247.30M$0.00-$153.22M
2022-12-31$19.71M(m)$174.96M$245.66M$0.00-$220.43M
2021-12-31$25.54M(m)$142.51M$218.69M$0.00-$192.50M
2020-12-31$90.73M(m)$158.00M$225.57M(m)-$115.98M
2019-12-31$20.53M(m)$96.90M$161.45M(m)-$133.75M
2018-12-31$31.94M$31.94M$90.65M$145.66M(m)-$109.95M
2017-12-31$13.73M(m)$83.16M$133.66M(m)-$120.32M
2016-12-31$6.05M(m)$56.98M$103.24M(m)-$97.18M
2015-12-31(m)(m)$18.85M$36.94M(m)-$72.90M
2014-12-31(m)(m)$5.07M$12.72M(m)-$13.69M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30